Taysha Gene Therapies, Inc. (TSHA) Q3 2022 Results - Earnings Call Transcript

Nov. 13, 2022 10:40 AM ETTaysha Gene Therapies, Inc. (TSHA)
SA Transcripts profile picture
SA Transcripts

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q3 2022 Results Earnings Conference Call November 8, 2022 8:00 AM ET

Company Participants

Kimberly Lee - Chief Corporate Affairs Officer

RA Session - President, Founder and Chief Executive Officer

Suyash Prasad - Chief Medical Officer and Head of Research and Development

Kamran Alam - Chief Financial Officer

Fred Porter - Chief Technical Officer

Conference Call Participants

Gil Blum - Needham & Company, LLC

Geulah Livshits - Chardan

Mehdi Goudarzi - Truist Securities

Michael Ulz - Morgan Stanley

David Hoang - SMBC Nikko

Benjamin Paluch - Robert W. Baird

Yanan Zhu - Wells Fargo

Tiffany Marchell - William Blair

Whitney Ijem - Canaccord Genuity


Thank you for standing by. Welcome to Taysha Gene Therapies Third Quarter 2022 Financial Results and Corporate Update Conference Call. At this time, all participants are in listen-only mode. Following management's prepared remarks, we will hold a brief question-and-answer session. As a reminder, this call is being recorded today, November 8, 2022.

I will now turn the call over to Dr. Kimberly Lee, Chief Corporate Affairs Officer. Please go ahead.

Kimberly Lee

Good morning, and welcome to Taysha's third quarter 2022 financial results and corporate update conference call. Joining me on today's call are RA Session, II Taysha's President, Founder and CEO; Dr. Suyash Prasad, Chief Medical Officer and Head of R&D; and Kamran Alam, Chief Financial Officer. After our formal remarks, we will conduct a question-and-answer session and instructions will follow at that time.

Earlier today, Taysha issued a press release announcing financial results for the second quarter ending September 30, 2022. A copy of this press release is available on the company's website and through our SEC filings.

Please note that, on today's call, we will be making forward-looking statements, including statements relating to the safety and efficacy and the therapeutic

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.